Relationship between intestinal microorganisms and T lymphocytes in colorectal cancer

References

• 1. Mitchell AB, Glanville AR. The human respiratory microbiome: implications and impact. Semin. Respir. Crit. Care Med. 39(2), 199–212 (2018).
  MedlineGoogle Scholar
• 2. Han S, Gao J, Zhou Q et al. Role of intestinal flora in colorectal cancer from the metabolite perspective: a systematic review. Cancer Manag. Res. 10, 199–206 (2018).
  Medline CASGoogle Scholar
• 3. Ohtani N. Microbiome and cancer. Semin. Immunopathol. 37(1), 65–72 (2015).
  Medline CASGoogle Scholar
• 4. Sheflin AM, Whitney AK, Weir TL. Cancer-promoting effects of microbial dysbiosis. Curr. Oncol. Rep. 16(10), 406 (2014).
  MedlineGoogle Scholar
• 5. Chen GY. The role of the gut microbiome in colorectal cancer. Clin. Colon Rectal Surg. 31(3), 192–198 (2018).
  MedlineGoogle Scholar
• 6. Gagniere J, Bonnin V, Jarrousse AS et al. Interactions between microsatellite instability and human gut colonization by Escherichia coli in colorectal cancer. Clin. Sci. 131(6), 471–485 (2017).
  Medline CASGoogle Scholar
• 7. Andrews MC, Reuben A, Gopalakrishnan V, Wargo JA. Concepts collide: genomic, immune, and microbial influences on the tumor microenvironment and response to cancer therapy. Front. Immunol. 9, 946 (2018).
  MedlineGoogle Scholar
• 8. Sun J. Enteric bacteria and cancer stem cells. Cancers 3(1), 285–297 (2010).
  MedlineGoogle Scholar
• 9. Wassenaar TM. E coli and colorectal cancer: a complex relationship that deserves a critical mindset. Crit. Rev. Microbiol. 44(5), 619–632 (2018).
  MedlineGoogle Scholar
• 10. Niederreiter L, Adolph TE, Tilg H. Food, microbiome and colorectal cancer. Dig. Liver Dis. 50(7), 647–652 (2018).
  MedlineGoogle Scholar
• 11. Xie YH, Gao QY, Cai GX et al. Fecal Clostridium symbiosum for noninvasive detection of early and advanced colorectal cancer: test and validation studies. EBioMedicine 25, 32–40 (2017).
  Medline CASGoogle Scholar
• 12. Viljoen KS, Dakshinamurthy A, Goldberg P et al. Quantitative profiling of colorectal cancer-associated bacteria reveals associations between Fusobacterium spp., enterotoxigenic Bacteroides fragilis (ETBF) and clinicopathological features of colorectal cancer. PLoS ONE 10(3), e119462 (2015).
  Google Scholar
• 13. Han A, Bennett N, Ahmed B et al. Butyrate decreases its own oxidation in colorectal cancer cells through inhibition of histone deacetylases. Oncotarget 9(43), 27280–27292 (2018).
  MedlineGoogle Scholar
• 14. Ohara T, Suzutani T. Intake of Bifidobacterium longum and fructo-oligosaccharides prevents colorectal carcinogenesis. Euroasian J. Hepatogastroenterol. 8(1), 11–17 (2018).
  MedlineGoogle Scholar
• 15. Casanova MR, Azevedo-Silva J, Rodrigues LR, Preto A. Colorectal cancer cells increase the production of short chain fatty acids by Propionibacterium freudenreichii impacting on cancer cells survival. Front. Nutr. 5, 44 (2018).
  MedlineGoogle Scholar
• 16. Pasquereau-Kotula E, Martins M, Aymeric L, Dramsi S. Significance of Streptococcus gallolyticus subsp. gallolyticus association with colorectal cancer. Front. Microbiol. 9, 614 (2018).
  MedlineGoogle Scholar
• 17. Lewis SB, Prior A, Ellis SJ et al. Flagellin induces beta-Defensin 2 in human colonic ex vivo infection with enterohemorrhagic Escherichia coli. . Front. Cell. Infect. Microbiol. 6, 68 (2016).
  MedlineGoogle Scholar
• 18. Tian PJ, Li BL, Shan YJ et al. Extraction of Peptidoglycan from L. paracasei subp. paracasei X12 and its preliminary mechanisms of inducing immunogenic cell death in HT-29 Cells. Int. J. Mol. Sci. 16(8), 20033–20049 (2015).
  Medline CASGoogle Scholar
• 19. Li TT, Ogino S, Qian ZR. Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy. World J. Gastroenterol. 20(47), 17699–17708 (2014).
  MedlineGoogle Scholar
• 20. Elinav E, Henao-Mejia J, Flavell RA. Integrative inflammasome activity in the regulation of intestinal mucosal immune responses. Mucosal Immunol. 6(1), 4–13 (2013).
  Medline CASGoogle Scholar
• 21. Arthur JC, Jobin C. The struggle within: microbial influences on colorectal cancer. Inflamm. Bowel Dis. 17(1), 396–409 (2011).
  MedlineGoogle Scholar
• 22. Messaritakis I, Stogiannitsi M, Koulouridi A et al. Evaluation of the detection of Toll-like receptors (TLRs) in cancer development and progression in patients with colorectal cancer. PLoS ONE 13(6), e197327 (2018).
  Google Scholar
• 23. Sackstein R, Schatton T, Barthel SR. T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy. Lab. Invest. 97(6), 669–697 (2017).
  Medline CASGoogle Scholar
• 24. Teramoto K, Ohshio Y, Fujita T, Hanaoka J, Kontani K. Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy. J. Cancer Res. Clin. Oncol. 139(5), 861–870 (2013).
  Medline CASGoogle Scholar
• 25. Mucida D, Husain MM, Muroi S et al. Transcriptional reprogramming of mature CD4(+) helper T cells generates distinct MHC class II-restricted cytotoxic T lymphocytes. Nat. Immunol. 14(3), 281–289 (2013).
  Medline CASGoogle Scholar
• 26. Marisa L, Svrcek M, Collura A et al. The balance between cytotoxic T-cell lymphocytes and immune checkpoint expression in the prognosis of colon tumors. J. Natl Cancer Inst. 110(1), doi:10.1093/jnci/djx 136 (2018).
  Google Scholar
• 27. Church SE, Galon J. Regulation of CTL infiltration within the tumor microenvironment. Adv. Exp. Med. Biol. 1036, 33–49 (2017).
  Medline CASGoogle Scholar
• 28. Olguin JE, Medina-Andrade I, Molina E et al. Early and partial reduction in CD4(+)Foxp3(+) regulatory T cells during colitis-associated colon cancer induces CD4(+) and CD8(+) T cell activation inhibiting tumorigenesis. J. Cancer 9(2), 239–249 (2018).
  MedlineGoogle Scholar
• 29. Sideras K, Galjart B, Vasaturo A et al. Prognostic value of intra-tumoral CD8(+) /FoxP3(+) lymphocyte ratio in patients with resected colorectal cancer liver metastasis. J. Surg. Oncol. 118(1), 68–76 (2018).
  Medline CASGoogle Scholar
• 30. Zhu XW, Zhu HZ, Zhu YQ et al. Foxp3 expression in CD4(+)CD25(+)Foxp3(+) regulatory T cells promotes development of colorectal cancer by inhibiting tumor immunity. J. Huazhong Univ. Sci. Technolog. Med. Sci. 36(5), 677–682 (2016).
  Medline CASGoogle Scholar
• 31. Fujimoto H, Saito Y, Ohuchida K et al. Deregulated mucosal immune surveillance through gut-associated regulatory T cells and PD-1(+) T cells in human colorectal cancer. J. Immunol. 200(9), 3291–3303 (2018).
  Medline CASGoogle Scholar
• 32. Zhong W, Jiang ZY, Zhang L et al. Role of LAP(+)CD4(+) T cells in the tumor microenvironment of colorectal cancer. World J. Gastroenterol. 23(3), 455–463 (2017).
  Medline CASGoogle Scholar
• 33. Raghavan S, Quiding-Jarbrink M. Regulatory T cells in gastrointestinal tumors. Expert Rev. Gastroenterol. Hepatol. 5(4), 489–501 (2011).
  Medline CASGoogle Scholar
• 34. Hu G, Wu P, Cheng P et al. Tumor-infiltrating CD39(+)gammadeltaTregs are novel immunosuppressive T cells in human colorectal cancer. Oncoimmunology 6(2), e1277305 (2017).
  MedlineGoogle Scholar
• 35. Seebauer CT, Brunner S, Glockzin G et al. Peritoneal carcinomatosis of colorectal cancer is characterized by structural and functional reorganization of the tumor microenvironment inducing senescence and proliferation arrest in cancer cells. Oncoimmunology 5(12), e1242543 (2016).
  MedlineGoogle Scholar
• 36. Cremonesi E, Governa V, Garzon J et al. Gut microbiota modulate T cell trafficking into human colorectal cancer. Gut 67(11), 1984–1994 (2018).
  Medline CASGoogle Scholar
• 37. Thiele OE, Fan H, Tam AJ et al. The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine colon tumorigenesis. Mucosal Immunol. 10(2), 421–433 (2017).
  MedlineGoogle Scholar
• 38. Yuvaraj S, Al-Lahham S, Marreddy RK et al. Human scFv SIgA expressed on Lactococcus lactis as a vector for the treatment of mucosal disease. Mol. Nutr. Food Res. 52(8), 913–920 (2008).
  Medline CASGoogle Scholar
• 39. Vo MC, Lee HJ, Kim JS et al. Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity. Oncotarget 6(32), 33781–33790 (2015).
  MedlineGoogle Scholar
• 40. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat. Rev. Immunol. 10(2), 131–144 (2010).
  Medline CASGoogle Scholar
• 41. Kempski J, Brockmann L, Gagliani N, Huber S. TH17 cell and epithelial cell crosstalk during inflammatory bowel disease and carcinogenesis. Front. Immunol. 8, 1373 (2017).
  MedlineGoogle Scholar
• 42. Deng Z, Mu J, Tseng M et al. Enterobacteria-secreted particles induce production of exosome-like S1P-containing particles by intestinal epithelium to drive Th17-mediated tumorigenesis. Nat. Commun. 6, 6956 (2015).
  Medline CASGoogle Scholar
• 43. Wick EC, Rabizadeh S, Albesiano E et al. Stat3 activation in murine colitis induced by enterotoxigenic Bacteroides fragilis. Inflamm. Bowel Dis. 20(5), 821–834 (2014).
  MedlineGoogle Scholar
• 44. Girardin A, McCall J, Black MA et al. Inflammatory and regulatory T cells contribute to a unique immune microenvironment in tumor tissue of colorectal cancer patients. Int. J. Cancer 132(8), 1842–1850 (2013).
  Medline CASGoogle Scholar
• 45. Sarrabayrouse G, Bossard C, Chauvin JM et al. CD4CD8alphaalpha lymphocytes, a novel human regulatory T cell subset induced by colonic bacteria and deficient in patients with inflammatory bowel disease. PLoS Biol. 12(4), e1001833 (2014).
  MedlineGoogle Scholar
• 46. Erdman SE, Poutahidis T. Roles for inflammation and regulatory T cells in colon cancer. Toxicol. Pathol. 38(1), 76–87 (2010).
  Medline CASGoogle Scholar
• 47. Mima K, Ogino S, Nakagawa S et al. The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms. Surg. Oncol. 26(4), 368–376 (2017).
  MedlineGoogle Scholar
• 48. Rezasoltani S, Asadzadeh-Aghdaei H, Nazemalhosseini-Mojarad E, Dabiri H, Ghanbari R, Zali MR. Gut microbiota, epigenetic modification and colorectal cancer. Iran J. Microbiol. 9(2), 55–63 (2017).
  MedlineGoogle Scholar
• 49. Pang X, Tang YJ, Ren XH et al. Microbiota, epithelium, inflammation, and TGF-beta signaling: an intricate interaction in oncogenesis. Front. Microbiol. 9, 1353 (2018).
  MedlineGoogle Scholar
• 50. Hu G, Li Z, Wang S. Tumor-infiltrating FoxP3(+) Tregs predict favorable outcome in colorectal cancer patients: a meta-analysis. Oncotarget 8(43), 75361–75371 (2017).
  MedlineGoogle Scholar
• 51. Yan G, Liu T, Yin L, Kang Z, Wang L. Levels of peripheral Th17 cells and serum Th17-related cytokines in patients with colorectal cancer: a meta-analysis. Cell. Mol. Biol. 64(6), 94–102 (2018).
  MedlineGoogle Scholar
• 52. Limagne E, Euvrard R, Thibaudin M et al. Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX-bevacizumab drug treatment regimen. Cancer Res. 76(18), 5241–5252 (2016).
  Medline CASGoogle Scholar
• 53. Heyman M, Menard S. Probiotic microorganisms: how they affect intestinal pathophysiology. Cell. Mol. Life Sci. 59(7), 1151–1165 (2002).
  Medline CASGoogle Scholar
• 54. Kawakami H, Zaanan A, Sinicrope FA. Microsatellite instability testing and its role in the management of colorectal cancer. Curr. Treat. Options Oncol. 16(7), 30 (2015).
  MedlineGoogle Scholar
• 55. Mlecnik B, Bindea G, Angell HK et al. Integrative analyses of colorectal cancer show Immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 44(3), 698–711 (2016).
  Medline CASGoogle Scholar
• 56. Webber EM, Kauffman TL, O’Connor E et al. Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy. BMC Cancer 15, 156 (2015).
  MedlineGoogle Scholar
• 57. Patel SA, Longacre TA, Ladabaum U et al. Tumor molecular testing guides anti-PD-1 therapy and provides evidence for pathogenicity of mismatch repair variants. Oncologist 23(12), 1395–1400 (2018).
  Medline CASGoogle Scholar
• 58. Gagniere J, Bonnin V, Jarrousse AS et al. Interactions between microsatellite instability and human gut colonization by Escherichia coli in colorectal cancer. Clin. Sci. 131(6), 471–485 (2017).
  Medline CASGoogle Scholar
• 59. Miyauchi T, Yaguchi T, Kawakami Y. Inter-patient and intra-tumor heterogeneity in the sensitivity to tumor-targeted immunity in colorectal cancer. Nihon Rinsho Meneki Gakkai Kaishi 40(1), 54–59 (2017).
  Medline CASGoogle Scholar
• 60. Nosho K, Sukawa Y, Adachi Y et al. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J. Gastroenterol. 22(2), 557–566 (2016).
  Medline CASGoogle Scholar
• 61. Han YW. Fusobacterium nucleatum: a commensal-turned pathogen. Curr. Opin. Microbiol. 23, 141–147 (2015).
  Medline CASGoogle Scholar
• 62. Kostic AD, Chun E, Robertson L et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14(2), 207–215 (2013).
  Medline CASGoogle Scholar
• 63. Bashir A, Miskeen AY, Bhat A et al. Fusobacterium nucleatum: an emerging bug in colorectal tumorigenesis. Eur. J. Cancer Prev. 24(5), 373–385 (2015).
  Medline CASGoogle Scholar
• 64. Rubinstein MR, Wang X, Liu W et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe 14(2), 195–206 (2013).
  Medline CASGoogle Scholar
• 65. Abed J, Emgard JE, Zamir G et al. Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe 20(2), 215–225 (2016).
  Medline CASGoogle Scholar
• 66. Yu T, Guo F, Yu Y et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 170(3), 548–563 (2017).
  Medline CASGoogle Scholar
• 67. Geller LT, Barzily-Rokni M, Danino T et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357(6356), 1156–1160 (2017).
  Medline CASGoogle Scholar
• 68. Shenker BJ, Datar S. Fusobacterium nucleatum inhibits human T-cell activation by arresting cells in the mid-G1 phase of the cell cycle. Infect. Immun. 63(12), 4830–4836 (1995).
  Medline CASGoogle Scholar
• 69. Kinder HS, Lindemann RA. Fusobacterium nucleatum T18 aggregates human mononuclear cells and inhibits their PHA-stimulated proliferation. J. Periodontol. 68(1), 39–44 (1997).
  MedlineGoogle Scholar
• 70. Chen T, Li Q, Zhang X et al. TOX expression decreases with progression of colorectal cancers and is associated with CD4 T-cell density and Fusobacterium nucleatum infection. Hum. Pathol. 79, 93–101 (2018).
  Medline CASGoogle Scholar
• 71. Suschak JJ, Bagley K, Shoemaker CJ et al. The genetic adjuvants interleukin-12 and granulocyte-macrophage colony stimulating factor enhance the immunogenicity of an Ebola virus deoxyribonucleic acid vaccine in mice. J. Infect. Dis. 218(Suppl. 5), S519–S527 (2018).
  MedlineGoogle Scholar
• 72. Jahn-Schmid B, Siemann U, Zenker A et al. Bet v 1, the major birch pollen allergen, conjugated to crystalline bacterial cell surface proteins, expands allergen-specific T cells of the Th1/Th0 phenotype in vitro by induction of IL-12. Int. Immunol. 9(12), 1867–1874 (1997).
  Medline CASGoogle Scholar
• 73. Yu S, Jia L, Zhang Y et al. IL-12 induced the generation of IL-21- and IFN-gamma-co-expressing poly-functional CD4+ T cells from human naive CD4+ T cells. Cell Cycle 14(21), 3362–3372 (2015).
  MedlineGoogle Scholar
• 74. Hester CM, Jala VR, Langille MG et al. Fecal microbes, short chain fatty acids, and colorectal cancer across racial/ethnic groups. World J. Gastroenterol. 21(9), 2759–2769 (2015).
  Medline CASGoogle Scholar
• 75. Yu Z, Song G, Liu J et al. Beneficial effects of extracellular polysaccharide from Rhizopus nigricans on the intestinal immunity of colorectal cancer mice. Int. J. Biol. Macromol. 115, 718–726 (2018).
  Medline CASGoogle Scholar
• 76. Nowak A, Slizewska K, Otlewska A. Antigenotoxic activity of lactic acid bacteria, prebiotics, and products of their fermentation against selected mutagens. Regul. Toxicol. Pharmacol. 73(3), 938–946 (2015).
  Medline CASGoogle Scholar
• 77. Thirabunyanon M, Hongwittayakorn P. Potential probiotic lactic acid bacteria of human origin induce antiproliferation of colon cancer cells via synergic actions in adhesion to cancer cells and short-chain fatty acid bioproduction. Appl. Biochem. Biotechnol. 169(2), 511–525 (2013).
  Medline CASGoogle Scholar
• 78. Jan G, Belzacq AS, Haouzi D et al. Propionibacteria induce apoptosis of colorectal carcinoma cells via short-chain fatty acids acting on mitochondria. Cell Death Differ. 9(2), 179–188 (2002).
  Medline CASGoogle Scholar
• 79. Mu C, Yang Y, Luo Z, Guan L, Zhu W. The colonic microbiome and epithelial transcriptome are altered in rats fed a high-protein diet compared with a normal-protein diet. J. Nutr. 146(3), 474–483 (2016).
  Medline CASGoogle Scholar
• 80. GCJ Abell, Christophersen CT, McOrist AL, Clarke JM. Dietary resistant and butyrylated starches have different effects on the faecal bacterial flora of azoxymethane-treated rats. Br. J. Nutr. 105(10), 1480–1485 (2011).
  Medline CASGoogle Scholar
• 81. Ogino S, Nowak JA, Hamada T et al. Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. Gut 67(6), 1168–1180 (2018).
  Medline CASGoogle Scholar
• 82. Ogino S, Nowak JA, Hamada T et al. Insights into pathogenic interactions among environment, host, and tumor at the crossroads of molecular pathology and epidemiology. Annu. Rev. Pathol. 4, 83–103 (2019).
  Google Scholar
• 83. Shah MS, DeSantis TZ, Weinmaier T et al. Leveraging sequence-based faecal microbial community survey data to identify a composite biomarker for colorectal cancer. Gut 67(5), 882–891 (2018).
  Medline CASGoogle Scholar
• 84. Yoshida Y, Naito M, Yamada T et al. Adoptive chemoimmunotherapy using activated alphabeta T cells for stage IV colorectal cancer. Anticancer Res. 36(7), 3741–3746 (2016).
  Medline CASGoogle Scholar
• 85. Kuczma MP, Ding ZC, Li T et al. The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells. Oncotarget 8(67), 111931–111942 (2017).
  MedlineGoogle Scholar
• 86. Hamada T, Keum N, Nishihara R et al. Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. J. Gastroenterol. 52(3), 265–275 (2017).
  MedlineGoogle Scholar
• 87. Groza D, Gehrig S, Kudela P et al. Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis. Oncoimmunology 7(5), e1424676 (2018).
  MedlineGoogle Scholar
• 88. Park HE, Kim JH, Cho NY et al. Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma. Virchows Arch. 471(3), 329–336 (2017).
  Medline CASGoogle Scholar
• 89. Saito T, Nishikawa H, Wada H et al. Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat. Med. 22(6), 679–684 (2016).
  Medline CASGoogle Scholar
• 90. Lenoir M, Del CS, Cortes-Perez NG et al. Lactobacillus casei BL23 regulates Treg and Th17 T-cell populations and reduces DMH-associated colorectal cancer. J. Gastroenterol. 51(9), 862–873 (2016).
  Medline CASGoogle Scholar
• 91. Bhattacharya N, Yuan R, Prestwood TR et al. Normalizing microbiota-induced retinoic acid deficiency stimulates protective CD8(+) T cell-mediated immunity in colorectal cancer. Immunity 45(3), 641–655 (2016).
  Medline CASGoogle Scholar
• 92. Stern C, Kasnitz N, Kocijancic D et al. Induction of CD4(+) and CD8(+) anti-tumor effector T cell responses by bacteria mediated tumor therapy. Int. J. Cancer 137(8), 2019–2028 (2015).
  Medline CASGoogle Scholar
• 93. Mima K, Sukawa Y, Nishihara R et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 1(5), 653–661 (2015).
  MedlineGoogle Scholar
• 94. Jiang Y, Lin J, Zhang D et al. Bacterial translocation contributes to cachexia and its possible pathway in patients with colon cancer. J. Clin. Gastroenterol. 48(2), 131–137 (2014).
  Medline CASGoogle Scholar
• 95. Huang T, Li S, Li G et al. Utility of Clostridium difficile toxin B for inducing anti-tumor immunity. PLoS ONE 9(10), e110826 (2014).
  MedlineGoogle Scholar
• 96. Nguyen DD, Muthupalani S, Goettel JA et al. Colitis and colon cancer in WASP-deficient mice require Helicobacter species. Inflamm. Bowel Dis. 19(10), 2041–2050 (2013).
  MedlineGoogle Scholar
• 97. Zimmerman MA, Singh N, Martin PM et al. Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. Am. J. Physiol. Gastrointest. Liver Physiol. 302(12), G1405–G1415 (2012).
  Medline CASGoogle Scholar
• 98. Bassaganya-Riera J, Viladomiu M, Pedragosa M et al. Immunoregulatory mechanisms underlying prevention of colitis-associated colorectal cancer by probiotic bacteria. PLoS ONE 7(4), e34676 (2012).
  Medline CASGoogle Scholar
• 99. Wu S, Rhee KJ, Albesiano E et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med. 15(9), 1016–1022 (2009).
  Medline CASGoogle Scholar
• 100. Erdman SE, Poutahidis T, Tomczak M et al. CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am. J. Pathol. 162(2), 691–702 (2003).
  Medline CASGoogle Scholar
• 101. Kado S, Uchida K, Funabashi H et al. Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta chain and p53 double-knockout mice. Cancer Res. 61(6), 2395–2398 (2001).
  Medline CASGoogle Scholar
• 102. Maeurer M, Zitvogel L, Elder E et al. Human intestinal V delta 1+ T cells obtained from patients with colon cancer respond exclusively to SEB but not to SEA. Nat. Immun. 14(4), 188–197 (1995).
  Medline CASGoogle Scholar